Skip to content

Study · In vitro (cells) · rat · 1997

4 results

Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insensitive to GH-releasing hormone.

Giustina A, Bonfanti C, Licini M, Ragni G, Stefana B

Regulatory peptides1 May 1997Cited by 10 (Europe PMC)

PMID9250581 (opens in a new tab)DOI10.1016/s0167-0115(97)00017-7 (opens in a new tab)PepBankPUB-09250581
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In GH1 rat tumor cells, hexarelin significantly stimulated GH release, with the greatest effect at 1 microM.

    In plain wordsIn rat tumour cells that do not respond to GHRH, hexarelin raised growth hormone release, most at 1 microM.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH release in GH1 cells
    Study

    ratn: not reported in source

    GH1 rat tumor cell line, insensitive to GHRH
    Comparator
    Control wells
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.01-1 microMAs given in this study (rat).

    Measurements

    GH release
    155 % vs control wells
    GH1 cells, 1 microM

    Source sentences

    Summary
    The GHRP-6 analog hexarelin (0.01-1 microM) significantly stimulated GH release in both normal and GH1 rat cells.
    2 context sentences
    Summary · context
    The greatest GH-releasing effect of hexarelin was observed with the 1 microM dose both in GH1 (155+/-25% vs. control wells) and in normal rat pituitary cells (185+/-23% vs. control wells).
    Summary · context
    The aim of the study was to assess for the first time the effect on GH secretion of the GHRP-6 analog, hexarelin, in the GH1 cells; moreover, we investigated the potential involvement of GHRH in the effects of hexarelin in the GH1 rat cell line.
  2. 02LabIn vitro (cells)Activity measurement

    In normal rat pituitary cells, hexarelin significantly stimulated GH release, with the greatest effect at 1 microM.

    In plain wordsIn normal rat pituitary cells, hexarelin raised growth hormone release, most at 1 microM.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH release in normal rat pituitary cells
    Study

    ratn: not reported in source

    Normal rat pituitary cells
    Comparator
    Control wells
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.01-1 microMAs given in this study (rat).

    Measurements

    GH release
    185 % vs control wells
    normal rat pituitary cells, 1 microM

    Source sentences

    Summary
    The GHRP-6 analog hexarelin (0.01-1 microM) significantly stimulated GH release in both normal and GH1 rat cells.
    2 context sentences
    Summary · context
    The greatest GH-releasing effect of hexarelin was observed with the 1 microM dose both in GH1 (155+/-25% vs. control wells) and in normal rat pituitary cells (185+/-23% vs. control wells).
    Summary · context
    The aim of the study was to assess for the first time the effect on GH secretion of the GHRP-6 analog, hexarelin, in the GH1 cells; moreover, we investigated the potential involvement of GHRH in the effects of hexarelin in the GH1 rat cell line.

Studies that did not test the peptide alone2

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 03LabNot a test of Hexarelin aloneIn vitro (cells)Activity measurement

    In normal rat pituitary cells, GHRH and hexarelin together had additive stimulatory effects on GH secretion.

    In plain wordsIn normal rat pituitary cells, GHRH and hexarelin together raised growth hormone release in an additive way.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH secretion with GHRH plus hexarelin
    Study

    ratn: not reported in source

    Normal rat pituitary cells
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    In this latter cell model, GHRH and hexarelin were demonstrated to have additive stimulatory effects on GH secretion.
    1 context sentence
    Summary · context
    The aim of the study was to assess for the first time the effect on GH secretion of the GHRP-6 analog, hexarelin, in the GH1 cells; moreover, we investigated the potential involvement of GHRH in the effects of hexarelin in the GH1 rat cell line.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 04LabNot a test of Hexarelin aloneIn vitro (cells)Activity measurement

    In GH1 cells, GHRH did not change hexarelin-stimulated GH release at any dose used.

    In plain wordsIn rat tumour cells, adding GHRH did not change the growth hormone release caused by hexarelin.

    Peptide
    Hexarelin
    Outcome
    No significant changeEffect of GHRH on hexarelin-stimulated GH release in GH1 cells
    Study

    ratn: not reported in source

    GH1 rat tumor cell line, insensitive to GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Conversely, GHRH did not affect hexarelin-stimulated GH release in GH1 cells at any of the doses used.
    1 context sentence
    Summary · context
    The aim of the study was to assess for the first time the effect on GH secretion of the GHRP-6 analog, hexarelin, in the GH1 cells; moreover, we investigated the potential involvement of GHRH in the effects of hexarelin in the GH1 rat cell line.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.